💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tapinarof

CHEMBL259571 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
254.3 g/mol
LogP
4.6
Phase
4

Tapinarof is a first-in-class therapeutic aryl hydrocarbon receptor (AhR) agonist approved for the topical treatment of plaque psoriasis and atopic dermatitis in adults. By activating AhR, it normalizes skin barrier function, reduces pro-inflammatory cytokine production (including IL-17A, IL-22, and Th2 cytokines), and exerts antioxidant effects. Its non-steroidal mechanism offers an alternative to topical corticosteroids without the risk of skin atrophy.

الوزن الجزيئي

254,3200 g/mol

LogP

4,60

TPSA

40,50 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Psoriasis Systemic Lupus Erythematosus Atopic Dermatitis

آلية العمل

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O

                

                

                
                

                    
InChI

                    
InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H18O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
الروابط القابلة للدوران

                        
3

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Tapinarof is a first-in-class therapeutic aryl hydrocarbon receptor (AhR) agonist approved for the topical treatment of plaque psoriasis and atopic dermatitis in adults. By activating AhR, it normalizes skin barrier function, reduces pro-inflammatory cytokine production (including IL-17A, IL-22, and Th2 cytokines), and exerts antioxidant effects. Its non-steroidal mechanism offers an alternative to topical corticosteroids without the risk of skin atrophy.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tapinarof is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL259571.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6439522.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.